1) Q1 Performance Overview
- Boston Scientific reported Q1 2026 organic sales growth of 9.4%, achieving the high end of their guidance range of 8.5% to 10%.
- Adjusted EPS for the quarter was $0.80, reflecting a 6% increase year-over-year.
- Adjusted operating margin was 28%.
- The company is guiding for Q2 organic growth of 5% to 7% and has reduced full-year guidance to 6.5% to 8% due to unexpected headwinds.

2) Segment Highlights
- U.S. Growth: The U.S. market grew 11%, with five out of eight business units showing double-digit growth.
- International Performance: EMEA grew 1% operationally, impacted by the discontinuation of POLARx and ACURATE.
- Asia Pacific: Strong performance with 12% growth, driven by Japan and China, particularly in the PFA ecosystem and imaging technologies.
- Urology: Sales grew only 1%, primarily due to challenges in stone management and neuromodulation.
- Endoscopy: Grew 7% with strong results from AXIOS.
- Neuromodulation: Strong growth of 15%, driven by a comprehensive portfolio.
- Cardiovascular: Grew 11%, with ICVT and vascular therapies performing well despite challenges in the arterial business in China.

3) Challenges and Headwinds
- The company faced unexpected challenges in WATCHMAN, EP, and Urology segments, leading to a downward revision in guidance.
- WATCHMAN growth was below expectations due to a deceleration in stand-alone procedures, influenced by hospital capacity and evolving reimbursement dynamics.
- Urology's performance was hindered by commercial turnover and product gaps, particularly in the stone management business.
- The EP business experienced increased competition, leading to share erosion.

4) Strategic Plans and Product Launches
- Boston Scientific is focused on improving Urology performance through hiring and training new sales representatives.
- The company anticipates launching new products, including insulin urethroscope and enhancements in the PFA ecosystem.
- WATCHMAN will see increased commercial investments to leverage recent clinical data and expand its market presence.
- Upcoming product launches in 2027 include the next-generation FARAPULSE and FANAFLEX catheters.

5) Guidance and Outlook
- Full-year adjusted EPS is now expected to be between $3.34 and $3.41, representing 9% to 11% growth.
- The company plans to repurchase approximately $2 billion of shares in Q2, indicating confidence in its long-term strategy despite the recent challenges.
- The outlook for 2026 reflects a more cautious approach, with expectations for improved performance in the latter half of the year.

Bottom line: Boston Scientific's Q1 results showcased solid growth, but unexpected challenges in key segments have led to a cautious outlook for the remainder of 2026. The company remains committed to strategic investments and product launches that are expected to drive long-term growth, making it a potentially attractive opportunity for investors looking for recovery in 2027.